Physician profile
Casey A Leamon
NPI 1811487333
$1,816.32
in general payments reported to CMS, 2019-2025
22 companies · $259 in 2025
The $259 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.40 · 2021: $53.31 · 2022: $503 · 2023: $477 · 2024: $508 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,243.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $303.25 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $301.48 | 2022-2025 | |
| Lilly USA, LLC | $205.73 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Corium, LLC | $130.09 | 2022-2024 | Azstarys |
| Pfizer INC. | $128.26 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $91.87 | 2022-2024 | |
| Ironshore Pharmaceuticals INC. | $87.84 | 2022-2023 | Jornay Pm |
| Amgen INC. | $71.77 | 2021-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.31 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $61.85 | 2019-2025 | Gardasil 9, Capvaxive, Enflonsia |
| Glaxosmithkline, LLC. | $51.38 | 2022-2024 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company Ltd. | $50.55 | 2022 | |
| Supernus Pharmaceuticals, INC. | $46.85 | 2023 | Qelbree |
| Sanofi-Aventis U.S. LLC | $45.59 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.39 | 2024 | Xifaxan |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $32.06 | 2024-2025 | Dyanavel Xr |
| Exact Sciences Corporation | $31.59 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Medtronic, INC. | $26.08 | 2024 | Intellis Adaptivestim |
| Collegium Pharmaceutical, INC. | $18.86 | 2025 | Jornay Pm |
| Astrazeneca Pharmaceuticals Lp | $14.23 | 2025 | Airsupra |
| Dexcom, INC. | $14.09 | 2025 | Dexcom G6 Transmitter |
| Organon LLC | $6.20 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Leamon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.